TY - JOUR
T1 - Management of Hyperkalemia With Insulin and Glucose
T2 - Pearls for the Emergency Clinician
AU - Moussavi, Kayvan
AU - Fitter, Scott
AU - Gabrielson, Stephen Walter
AU - Koyfman, Alex
AU - Long, Brit
N1 - Funding Information:
MB, BL, and AK conceived the idea for this article and contributed substantially to the writing and editing of the review. This article did not use any grants or funding, and it has not been presented in abstract form. This clinical review has not been published, it is not under consideration for publication elsewhere, its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. This review does not reflect the views or opinions of the U.S. Government, Department of Defense, U.S. Army, U.S. Air Force, Brooke Army Medical Center, or SAUSHEC EM Residency Program.
Publisher Copyright:
© 2019
PY - 2019/7
Y1 - 2019/7
N2 - Background: Hyperkalemia is a common, potentially lethal clinical condition that accounts for a significant number of emergency department (ED) visits. Insulin and dextrose are frequently used to manage patients with hyperkalemia. Objective: This narrative review evaluates several myths concerning hyperkalemia treatment with insulin and dextrose in the ED and provides recommendations based on the current evidence. Discussion: Hyperkalemia is a life-threatening condition requiring emergent therapy. One of these therapies includes insulin with glucose. However, hypoglycemia after insulin use is a frequent complication during hyperkalemia management. The published literature suggests that low pretreatment glucose, no history of diabetes mellitus, female gender, abnormal renal function, and lower body weight increase the risk of hypoglycemia. Several strategies can reduce the risk of hypoglycemia with insulin therapy, which include using insulin 5 units or 0.1 units/kg instead of 10 units, administering dextrose 50 g instead of 25 g, or administering dextrose as a prolonged infusion instead of a rapid intravenous bolus. Because insulin may have a duration of action that exceeds dextrose, patients receiving insulin for hyperkalemia should be monitored for hypoglycemia hourly for at least 4–6 h after administration. Conclusion: Several myths surround hyperkalemia management with insulin and dextrose. This review evaluates the evidence concerning insulin and glucose for hyperkalemia and suggests several modifications to insulin and dextrose dosing to reduce the risk of hypoglycemia.
AB - Background: Hyperkalemia is a common, potentially lethal clinical condition that accounts for a significant number of emergency department (ED) visits. Insulin and dextrose are frequently used to manage patients with hyperkalemia. Objective: This narrative review evaluates several myths concerning hyperkalemia treatment with insulin and dextrose in the ED and provides recommendations based on the current evidence. Discussion: Hyperkalemia is a life-threatening condition requiring emergent therapy. One of these therapies includes insulin with glucose. However, hypoglycemia after insulin use is a frequent complication during hyperkalemia management. The published literature suggests that low pretreatment glucose, no history of diabetes mellitus, female gender, abnormal renal function, and lower body weight increase the risk of hypoglycemia. Several strategies can reduce the risk of hypoglycemia with insulin therapy, which include using insulin 5 units or 0.1 units/kg instead of 10 units, administering dextrose 50 g instead of 25 g, or administering dextrose as a prolonged infusion instead of a rapid intravenous bolus. Because insulin may have a duration of action that exceeds dextrose, patients receiving insulin for hyperkalemia should be monitored for hypoglycemia hourly for at least 4–6 h after administration. Conclusion: Several myths surround hyperkalemia management with insulin and dextrose. This review evaluates the evidence concerning insulin and glucose for hyperkalemia and suggests several modifications to insulin and dextrose dosing to reduce the risk of hypoglycemia.
KW - adverse drug event
KW - hyperkalemia
KW - hypoglycemia
KW - insulin
KW - renal impairment
UR - http://www.scopus.com/inward/record.url?scp=85065414873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065414873&partnerID=8YFLogxK
U2 - 10.1016/j.jemermed.2019.03.043
DO - 10.1016/j.jemermed.2019.03.043
M3 - Article
C2 - 31084947
AN - SCOPUS:85065414873
SN - 0736-4679
VL - 57
SP - 36
EP - 42
JO - Journal of Emergency Medicine
JF - Journal of Emergency Medicine
IS - 1
ER -